Moderna, Inc. (MRNA) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Moderna is a biotechnology company advancing mRNA medicines. Key commercial products include the COVID-19 vaccine (Spikevax) and the recently approved RSV vaccine (mRESVIA), which received FDA approval in May 2024 for adults aged 60 and older. The company is transitioning its COVID-19 business from pandemic-driven demand to a seasonal commercial model.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $1,862 million | $1,831 million | $2,270 million | $4,037 million |
| Net Product Sales | $1,820 million | $1,757 million | $2,171 million | $3,878 million |
| Net Income (Loss) | $13 million | $(3,630) million | $(2,441) million | $(4,931) million |
| EPS (Diluted) | $0.03 | $(9.53) | $(6.37) | $(12.89) |
| Operating Cash Flow (9M) | $(3,829) million | $(3,740) million | — | — |
| Cash & Investments (Total) | $9,202 million | — | — | — |
| Working Capital | $7,465 million | — | — | — |
Note: Q3 2024 Net Income includes a $140 million favorable adjustment to prior period sales provisions. Cost of sales for Q3 2024 was $514 million, including $214 million in inventory write-downs.
Material Changes vs. Prior Period
- Revenue Stability: Q3 2024 total revenue increased slightly (2%) compared to Q3 2023, driven by a 4% increase in net product sales. This contrasts with a 44% revenue decline for the nine-month period year-over-year, reflecting the shift to seasonal demand.
- Profitability Improvement: The company returned to profitability in Q3 2024 ($13 million net income) compared to a significant loss in Q3 2023. This was driven by a 77% reduction in Cost of Sales (from $2.24 billion to $514 million) due to lower inventory write-downs and manufacturing optimization.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 36% in Q3 2024 compared to the prior year, attributed to reduced consulting and marketing spend. R&D expenses remained relatively flat (down 2%).
- Inventory Management: Inventory write-downs decreased significantly to $214 million in Q3 2024 from $1.3 billion in Q3 2023, though they remain a material cost component.
Guidance, Outlook, and Risks
- Outlook: Management anticipates further reductions in full-year 2024 COVID-19 sales compared to 2023 as the market evolves into a seasonal model. RSV sales commenced in Q3 2024 but are not expected to significantly impact full-year product sales. Cost of sales as a percentage of net product sales is expected to be lower in 2024 than the 70% experienced in 2023.
- Pipeline Updates:
- RSV: Positive Phase 3 results announced for high-risk adults aged 18-59.
- COVID-19: Positive Phase 3 data for next-generation vaccine (mRNA-1283).
- Flu: Discontinued standalone flu vaccine (mRNA-1010) accelerated approval pathway to focus on Flu+COVID combination vaccine (mRNA-1083).
- Discontinued Programs: Five programs discontinued in Q3 2024 to prioritize strategic efforts.
- Liquidity: As of September 30, 2024, the company held $9.2 billion in cash, cash equivalents, and investments. Management believes resources are sufficient to fund operations for at least the next 12 months.
- Risks & Contingencies:
- Legal Proceedings: New patent infringement lawsuits filed in October 2024 by GSK (regarding COVID-19 and RSV vaccines) and Northwestern University. A securities class action and derivative litigation were also filed in late 2024 regarding RSV vaccine statements.
- Market Transition: Continued decline in COVID-19 demand as the market shifts from pandemic to endemic/seasonal patterns.
Key Investor Verification Points
- Seasonality Impact: Verify the trajectory of Q4 2024 sales to confirm the anticipated seasonal demand for COVID-19 and RSV vaccines.
- Inventory Write-downs: Monitor future quarters for continued inventory write-downs as the company adjusts manufacturing capacity to lower demand forecasts.
- Legal Exposure: Assess the potential financial impact of the new patent litigation from GSK and Northwestern University filed in October 2024.
- RSV Commercialization: Track the uptake of the mRESVIA vaccine in the U.S. commercial market following its Q3 launch.
- Cash Burn Rate: Evaluate the sustainability of the current operating cash outflow (~$3.8 billion for 9M) against the $9.2 billion cash position.